Testosterone undecanoate - Marius Pharmaceuticals

Drug Profile

Testosterone undecanoate - Marius Pharmaceuticals

Alternative Names: MRS 2012; SOV-2012-F1; T-replacement therapy - Marius

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator SOV Therapeutics
  • Developer Marius Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypogonadism
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypogonadism

Most Recent Events

  • 20 Mar 2017 Testosterone undecanoate is still at phase-IIb development stage for Hypogonadism (In adults) in USA (PO)
  • 16 Dec 2014 Phase-II clinical trials in Hypogonadism (In adults) in USA (PO)
  • 16 Dec 2014 Efficacy, adverse events and pharmacokinetics data from a phase IIb trial in Hypogonadism released by SOV Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top